US6096336A
(en)
*
|
1996-01-30 |
2000-08-01 |
The Stehlin Foundation For Cancer Research |
Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
|
CA2628857C
(en)
*
|
1996-12-30 |
2011-09-13 |
Batelle Memorial Institute |
Formulation and method for treating neoplasms by inhalation
|
JP2001513105A
(ja)
*
|
1997-02-27 |
2001-08-28 |
フアルマシア・アンド・アツプジヨン・カンパニー |
塩酸イリノテカン誘発性下痢軽減治療薬としてのタモキシフェン
|
US6114376A
(en)
*
|
1997-04-30 |
2000-09-05 |
Mcgill University |
Methods for using macrocyclic lactone compounds as multidrug resistance reversing agents in tumor and other cells
|
US6495591B1
(en)
|
1997-10-02 |
2002-12-17 |
Essential Therapeutics, Inc. |
Fungal efflux pump inhibitors
|
US6214821B1
(en)
*
|
1998-03-05 |
2001-04-10 |
Washington State University Research Foundation |
Methods and composition for the inhibition of cancer cells
|
WO1999047070A1
(en)
*
|
1998-03-18 |
1999-09-23 |
Wake Forest University |
Improved implantable biomaterials, compositions and methods for their preparation and uses thereof
|
US6706691B1
(en)
|
1998-07-15 |
2004-03-16 |
Board Of Regents, The University Of Texas System |
Immunosupportive drug sparing diet
|
US7772220B2
(en)
*
|
2004-10-15 |
2010-08-10 |
Seo Hong Yoo |
Methods and compositions for reducing toxicity of a pharmaceutical compound
|
US6204257B1
(en)
*
|
1998-08-07 |
2001-03-20 |
Universtiy Of Kansas |
Water soluble prodrugs of hindered alcohols
|
US6706759B1
(en)
*
|
1998-09-08 |
2004-03-16 |
Charlotte-Mecklenburg Hospital Authority |
Method of treating cancer using dithiocarbamate derivatives
|
US7816403B2
(en)
*
|
1998-09-08 |
2010-10-19 |
University Of Utah Research Foundation |
Method of inhibiting ATF/CREB and cancer cell growth and pharmaceutical compositions for same
|
US6589987B2
(en)
|
1998-09-08 |
2003-07-08 |
Charlotte-Mecklenburg Hospital Authority |
Method of treating cancer using tetraethyl thiuram disulfide
|
US6548540B2
(en)
|
1998-09-08 |
2003-04-15 |
Charlotte-Mecklenburg Hospital Authority |
Method of treating cancer using dithiocarbamate derivatives
|
US6395481B1
(en)
|
1999-02-16 |
2002-05-28 |
Arch Development Corp. |
Methods for detection of promoter polymorphism in a UGT gene promoter
|
US6709465B2
(en)
|
1999-03-18 |
2004-03-23 |
Fossa Medical, Inc. |
Radially expanding ureteral device
|
US7214229B2
(en)
|
1999-03-18 |
2007-05-08 |
Fossa Medical, Inc. |
Radially expanding stents
|
NZ514918A
(en)
|
1999-04-28 |
2003-11-28 |
Univ Texas |
Compositions and methods for cancer treatment by selectively inhibiting VEGF
|
ES2270834T3
(es)
*
|
1999-05-17 |
2007-04-16 |
Cancer Research Ventures Limited |
Composiciones para mejorar la biodisponibilidad de farmacos administrados oralmente.
|
US6228855B1
(en)
|
1999-08-03 |
2001-05-08 |
The Stehlin Foundation For Cancer Research |
Aromatic esters of camptothecins and methods to treat cancers
|
US6352996B1
(en)
|
1999-08-03 |
2002-03-05 |
The Stehlin Foundation For Cancer Research |
Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
|
US6734192B1
(en)
*
|
1999-08-23 |
2004-05-11 |
Mp-1 Inc. |
Treatment of viral infections
|
AU775373B2
(en)
|
1999-10-01 |
2004-07-29 |
Immunogen, Inc. |
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
|
US6191119B1
(en)
*
|
1999-10-15 |
2001-02-20 |
Supergen, Inc. |
Combination therapy including 9-nitro-20(S)-camptothecin
|
US6420378B1
(en)
*
|
1999-10-15 |
2002-07-16 |
Supergen, Inc. |
Inhibition of abnormal cell proliferation with camptothecin and combinations including the same
|
US6159935A
(en)
*
|
1999-11-29 |
2000-12-12 |
Pharmacia & Upjohn Co. |
Method for preventing diarrhea
|
PE20011042A1
(es)
*
|
2000-01-18 |
2001-09-26 |
Univ Massachusetts |
Uso de glutamina para la prevencion de diarrea de inicio tardio inducida por irinotecan
|
US7078045B2
(en)
*
|
2000-03-02 |
2006-07-18 |
Sang-Geon Kim |
Pharmaceutical composition for treatment and prevention of liver fibrosis and cirrhosis
|
WO2001066144A2
(en)
*
|
2000-03-08 |
2001-09-13 |
Rhode Island Hospital, A Lifespan Partner |
Antineoplastic combination comprising an inhibitor of angiogenesis and an inhibitor of dna topoisomerase i enzyme activity
|
US20030195161A1
(en)
*
|
2000-03-17 |
2003-10-16 |
Bissery Marie Christine |
Composition comprising camptothecin or a camptothecin derivative and a topoisomerase II inhibitor for the treatment of cancer
|
US6548488B2
(en)
*
|
2000-03-17 |
2003-04-15 |
Aventis Pharma S.A. |
Composition comprising camptothecin or a camptothecin derivative and an alkylating agent for the treatment of cancer
|
BR0109747A
(pt)
*
|
2000-04-07 |
2003-02-04 |
Sang-Geon Kim |
Uso de 5-(2-pirazinil)-4-metil-1-2-ditiol-3-tiona (oltipraz) como um medicamento, composição farmacêutica para a prevenção e tratamento da progressão da fibrose hepática, uso de 5-(2-pirazinil)-4-metil-1, 2-ditiol-3-tiona e método para a prevenção e tratamento da progressão da fibrose e da cirrose hepática
|
KR20030067935A
(ko)
*
|
2002-02-09 |
2003-08-19 |
김상건 |
올티프라즈를 포함하는 간경화(간경변증) 치료를 위한 간 조직 재생용 제약 조성물
|
AU2001259484A1
(en)
|
2000-05-05 |
2001-11-20 |
Wisconsin Alumni Research Foundation |
Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy
|
EP1486212A1
(de)
*
|
2000-06-01 |
2004-12-15 |
Sloan-Kettering Institute For Cancer Research |
Kombination von einem mutanten Herpesvirus mit Irinotecan zur Behandlung von Krebs
|
US7897559B2
(en)
*
|
2000-06-29 |
2011-03-01 |
Parks L Dean |
Dermatological composition and kit containing avermectin compound for treating dermatological conditions
|
US6319945B1
(en)
*
|
2000-06-29 |
2001-11-20 |
L. Dean Parks |
Method of treatment of seborrheic dermatitis
|
US6399651B1
(en)
*
|
2000-06-29 |
2002-06-04 |
L. Dean Parks |
Method of treating dermatoses using avermectin compound
|
US6353029B1
(en)
*
|
2000-08-24 |
2002-03-05 |
Bristol-Myers Squibb Company |
Storage stable tretinoin and 4-hydroxyanisole containing topical composition
|
US6624317B1
(en)
|
2000-09-25 |
2003-09-23 |
The University Of North Carolina At Chapel Hill |
Taxoid conjugates as antimitotic and antitumor agents
|
WO2002056872A2
(en)
*
|
2000-10-31 |
2002-07-25 |
Chemgenex Therapeutics, Inc. |
Antiproliferative colchicine compositions and uses thereof
|
US20050170015A1
(en)
*
|
2000-10-31 |
2005-08-04 |
Brown Dennis M. |
Antiproliferative colchicine compositions and uses thereof
|
SK7092003A3
(en)
|
2000-11-09 |
2004-06-08 |
Neopharm Inc |
SN-38 lipid complexes and methods of use
|
CA2430897C
(en)
*
|
2000-12-07 |
2010-11-16 |
Universiteit Utrecht Holding B.V. |
Liposomal composition comprising water-soluble corticosteroids for the treatment of inflammatory disorders
|
DE60142309D1
(de)
*
|
2000-12-12 |
2010-07-15 |
Nagoya Ind Science Res I Nagoy |
On einer durch die verabreichung einer verbindung, die entweder per se durch ugt1a1 metabolisiert wird oder deren zwischenverbindung durch das enzym metabolisiert wird, hervorgerufenen unerwünschten arzneimittelwirkung
|
WO2002059375A2
(en)
*
|
2001-01-26 |
2002-08-01 |
University Of Chicago |
Determination of ugt2b7 gene polymorphisms for predicting ugt2b7 substrate toxicity and for optimising drug dosage
|
WO2002069974A1
(en)
*
|
2001-03-05 |
2002-09-12 |
Andrew Holman |
Administration of sleep restorative agents
|
WO2002074246A2
(en)
*
|
2001-03-20 |
2002-09-26 |
New Century Pharmaceuticals, Inc. |
Method and compositions for optimizing blood and tissue stability of camptothecin and other albumin-binding therapeutic compounds
|
WO2003030864A1
(en)
*
|
2001-05-29 |
2003-04-17 |
Neopharm, Inc. |
Liposomal formulation of irinotecan
|
EP1554572B1
(de)
|
2001-07-25 |
2009-10-14 |
Raptor Pharmaceutical Inc. |
Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
|
WO2003025128A2
(en)
*
|
2001-09-14 |
2003-03-27 |
Duke University |
Quinone reductase 2 and aldehyde dehydrogenase as therapeutic targets
|
EP1293205A1
(de)
*
|
2001-09-18 |
2003-03-19 |
G2M Cancer Drugs AG |
Valproinsäure und deren Derivate zur Kombinationsbehandlung von Krebs beim Menschen und zur Behandlung von Tumor-Metastasen und minimaler Resterkrankung
|
US7199122B2
(en)
*
|
2001-10-02 |
2007-04-03 |
Fox Chase Cancer Center |
Methods for inhibiting angiogenesis
|
US20030194421A1
(en)
*
|
2001-12-28 |
2003-10-16 |
Angiotech Pharmaceuticals, Inc. |
Treatment of uveitis
|
US6977247B2
(en)
*
|
2002-02-21 |
2005-12-20 |
Supergen, Inc. |
Sequential therapy comprising a 20(S)-camptothecin and a pyrimidine base analog
|
US6627614B1
(en)
*
|
2002-06-05 |
2003-09-30 |
Super Gen, Inc. |
Sequential therapy comprising a 20(S)-camptothecin and an anthracycline
|
US20050152962A1
(en)
*
|
2002-06-12 |
2005-07-14 |
Metselaar Josbert M. |
Composition for treatment of inflammatory disorders
|
US20060030578A1
(en)
*
|
2002-08-20 |
2006-02-09 |
Neopharm, Inc. |
Pharmaceutically active lipid based formulation of irinotecan
|
WO2004035032A2
(en)
*
|
2002-08-20 |
2004-04-29 |
Neopharm, Inc. |
Pharmaceutical formulations of camptothecine derivatives
|
EP1393720A1
(de)
*
|
2002-08-27 |
2004-03-03 |
Universiteit Utrecht |
Vesikel enthaltend Corticosteroide zur Behandlung von Krebs
|
US20040157837A1
(en)
*
|
2002-11-07 |
2004-08-12 |
Serbedzija George N. |
Combinations for the treatment of fungal infections
|
US20040203034A1
(en)
*
|
2003-01-03 |
2004-10-14 |
The University Of Chicago |
Optimization of cancer treatment with irinotecan
|
US20040167165A1
(en)
*
|
2003-01-16 |
2004-08-26 |
Geetha Shankar |
Methods of treating conditions associated with an Edg-7 receptor
|
CA2514574A1
(en)
*
|
2003-01-30 |
2004-08-12 |
Dynogen Pharmaceuticals, Inc. |
Use of sodium channel modulators for treating gastrointestinal tract disorders
|
US6893668B2
(en)
*
|
2003-03-31 |
2005-05-17 |
Council Of Scientific And Industrial Research |
Process for isolation of anticancer agent camptothecin from Nothapodytes foetida
|
US20040248915A1
(en)
*
|
2003-04-25 |
2004-12-09 |
Jacques Jolivet |
Method for administration of troxacitabine
|
US7807350B2
(en)
*
|
2003-05-30 |
2010-10-05 |
The University Of Chicago |
Methods for predicting irinotecan toxicity
|
JP2007527241A
(ja)
*
|
2004-03-01 |
2007-09-27 |
ユニバーシティ オブ シカゴ |
上皮細胞成長因子受容体遺伝子プロモーターにおける多型
|
WO2005087952A1
(en)
*
|
2004-03-05 |
2005-09-22 |
The Regents Of The University Of California |
Methods and compositions relating to the pharmacogenetics of abcc2, ugt1a1, and/or slc01b1 gene variants
|
US20090247475A1
(en)
*
|
2004-03-05 |
2009-10-01 |
The Regents Of The University Of California |
Methods and compositions relating to pharmacogenetics of different gene variants in the context of irinotecan-based therapies
|
WO2005089639A2
(en)
*
|
2004-03-16 |
2005-09-29 |
Talarico M D Matthew T |
Method for vascular dysregulation
|
JP2008501708A
(ja)
*
|
2004-06-04 |
2008-01-24 |
スミスクライン ビーチャム (コーク) リミテッド |
がんの治療方法
|
JP4433918B2
(ja)
*
|
2004-07-15 |
2010-03-17 |
コニカミノルタエムジー株式会社 |
画像形成方法
|
KR100651728B1
(ko)
*
|
2004-11-10 |
2006-12-06 |
한국전자통신연구원 |
정착기를 갖는 전자 소자용 화합물 및 이를 포함하는 전자소자와 이들의 제조 방법
|
EP1861111A4
(de)
*
|
2005-03-02 |
2012-02-29 |
New Century Pharmaceuticals |
Verfahren und zusammensetzung zur erhöhung der sicherheit und effektivität albumin-bindender wirkstoffe
|
US20060222627A1
(en)
*
|
2005-03-30 |
2006-10-05 |
Andrew Carter |
Optimizing pharmacodynamics of therapeutic agents for treating vascular tissue
|
EP3827747A1
(de)
|
2005-04-28 |
2021-06-02 |
Otsuka Pharmaceutical Co., Ltd. |
Pharmainformatiksystem
|
EP1790343A1
(de)
*
|
2005-11-11 |
2007-05-30 |
Emotional Brain B.V. |
Pharmazeutische Zusammensetzungen und deren Verwendung zur Behandlung sexueller Störungen der Frau
|
JP2009535360A
(ja)
*
|
2006-04-26 |
2009-10-01 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
高分子量神経治療薬の対流増加送達のための組成物および方法
|
EP2063905B1
(de)
|
2006-09-18 |
2014-07-30 |
Raptor Pharmaceutical Inc |
Behandlungen von lebererkrankungen durch verabreichung von konjugaten aus rezeptor-assoziierten proteinen
|
US20100111874A1
(en)
*
|
2007-03-19 |
2010-05-06 |
University Of Medicine And Dentistry Of New Jresey |
Method of cancer detection and treatment
|
GB0811175D0
(en)
*
|
2008-06-18 |
2008-07-23 |
Prendergast Patrick T |
Anti-tumour compositions and methods
|
NZ616673A
(en)
|
2009-02-20 |
2014-08-29 |
To Bbb Holding B V |
Glutathione-based drug delivery system
|
ES2942923T3
(es)
|
2009-05-06 |
2023-06-07 |
Laboratory Skin Care Inc |
Composiciones de administración dérmica que comprenden complejos de agente activo-partículas de fosfato de calcio y métodos de uso de las mismas
|
US20120077778A1
(en)
|
2010-09-29 |
2012-03-29 |
Andrea Bourdelais |
Ladder-Frame Polyether Conjugates
|
WO2014022357A1
(en)
*
|
2012-07-30 |
2014-02-06 |
Isis Pharmaceuticals, Inc. |
Combination therapy for the treatment of cancer
|
WO2014152207A1
(en)
|
2013-03-15 |
2014-09-25 |
Mylan Laboratories, Inc. |
Hot melt granulation formulations of poorly water-soluble active agents
|
KR20160099081A
(ko)
|
2013-07-26 |
2016-08-19 |
업데이트 파마 인코포레이트 |
비산트렌의 치료 효과 개선용 조합 방법
|
US10098813B2
(en)
|
2014-09-03 |
2018-10-16 |
Sun Pharmaceutical Industries Limited |
Perfusion dosage form
|
US11554207B2
(en)
|
2016-02-09 |
2023-01-17 |
Sun Pharmaceutical Industries Ltd. |
Perfusion system
|
WO2020248824A1
(en)
*
|
2019-06-14 |
2020-12-17 |
Hsu Wen Ming |
Method and pharmaceutical composition for prevention and treatment of a cancer
|